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Live virus vaccines provide significant protection against many
detrimental human and animal diseases, but reversion to virulence
by mutation and recombination has reduced appeal. Using severe
acute respiratory syndrome coronavirus as a model, we engineered
a different transcription regulatory circuit and isolated recombi-
nant viruses. The transcription network allowed for efficient ex-
pression of the viral transcripts and proteins, and the recombinant
viruses replicated to WT levels. Recombinant genomes were then
constructed that contained mixtures of the WT and mutant regu-
latory circuits, reflecting recombinant viruses that might occur in
nature. Although viable viruses could readily be isolated from WT
and recombinant genomes containing homogeneous transcription
circuits, chimeras that contained mixed regulatory networks were
invariantly lethal, because viable chimeric viruses were not iso-
lated. Mechanistically, mixed regulatory circuits promoted ineffi-
cient subgenomic transcription from inappropriate start sites, re-
sulting in truncated ORFs and effectively minimize viral structural
protein expression. Engineering regulatory transcription circuits of
intercommunicating alleles successfully introduces genetic traps
into a viral genome that are lethal in RNA recombinant progeny
viruses.
regulation  systems biology  vaccine design
L ive virus vaccines represent a crucial intervention strategythat has been documented to improve the overall health of
populations. Concerns regarding reversion to virulence by mu-
tation and recombination, coupled with the associated chal-
lenges in developing these vaccines commercially, have dimin-
ished the appeal of live virus vaccines (1, 2). The dichotomy
between the well known protective efficacy and the costs and
risks of developing live virus vaccines has been recognized as a
Grand Challenge in Global Health by the National Foundation
for Infectious Diseases, which has called for new methods to
prevent reversion or recombination repair.
Severe acute respiratory syndrome coronavirus (SARS-CoV)
emerged suddenly and spread worldwide in 2003, causing 800
deaths (3). Zoonotic SARS-CoV strains, common in farm
animals and bats, dictate a need for continued surveillance and
the development of efficacious vaccines (4, 5). SARS-CoV is a
tractable system for innovative live virus vaccine design because
the pathogen is highly virulent and replicates efficiently in
animal models, and a robust reverse genetic system is available.
Importantly, CoVs undergo RNA recombination events at high
frequency, and recombination-mediated vaccine failures in an-
imals are a problem (6).
SARS-CoV contains a positive, single-stranded, 29,700-nt
RNA genome bound by the nucleocapsid protein (N) and an
envelope containing the S, ORF3a, E, andM structural proteins.
The SARS-CoV genome contains nine ORFs, and ORF1 en-
codes the viral replicase proteins that are required for sub-
genomic and genome-length RNA synthesis (7). Downstream of
ORF1 and interspaced among the structural genes are the
unique SARS-CoV group-specific genes (ORF3ab, ORF6,
ORF7ab, ORF8ab, and ORF9b) that are not necessary for
replication in cell culture (8). ORFs 2–8 are encoded in sub-
genomic mRNAs (mRNAs 2–9) synthesized as a nested set of 3
coterminal molecules. Leader RNA sequences, encoded at the
5 end of the genome, are joined to body sequences at distinct
transcription regulatory sequences (TRSs) that contain the core
sequence ACGAAC (7, 9). SARS-CoV likely uses transcription
attenuation to synthesize both full- and subgenomic-length neg-
ative strand RNAs containing antileader sequences, which then
function as the templates for the synthesis of like-sized mRNAs
(10, 11). Transcription attenuation is regulated by interactions
between a leader TRS (TRS-L) and body TRS (TRS-B) circuit
(12). Expression of each subgenomic mRNA requires extensive
communication by means of base pairing between the 5 end
TRS-L sequence and the appropriate TRS-B sequence. Most
studies support a strong role for a core consensus motif of six to
eight nucleotides that guide base pairing and duplex formation
between nascent negative strands and the TRS-L site at the 5
end of the genome. The interaction is assisted to a lesser extent
by surrounding (mostly downstream) sequences (12, 13).
In this report, we introduce a TRS circuit that regulates
efficient expression of the SARS-CoV subgenomic mRNAs.
Importantly, recombination events with WT virus trigger lethal
incompatibilities in the TRS circuitry, restricting the number of
viable recombinant viruses. This study provides an example of a
successful redesign of the regulatory circuit of a mammalian
virus.
Results
TRS Function in SARS-CoV Transcription. To remodel the SARS-
CoV TRS circuit, we replaced the nonessential ORF7ab do-
main with the Renilla luciferase gene under the control of the
ORF7ab TRS-B (icSARS-CoV Luc). We then engineered
double (icSARS-CoV Luc1) and triple (icSARS-CoV Luc2)
mutations that should specifically disrupt the ORF7ab TRS-B
circuit, theoretically blocking efficient mRNA 7 transcription.
The WT SARS-CoV TRS-B (ACGAAC) was replaced with
double (TRS-1, ACGGAT) and triple (TRS-2, CCGGAT) mu-
tations, the latter not being encoded elsewhere in the Urbani
genome (Fig. 1A). In fact, the remodeled TRS-2 sequence is
unique among CoVs.
Consistent with reports describing a SARS ORF7ab GFP
replacement virus (14), icSARS-CoV Luc replicated like WT
virus, achieving titers of 2  107 pfuml within 20 h after
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infection. In icSARS-CoV Luc-infected cells, Renilla luciferase
expression peaked at 5 logs above background (Fig. 2A).
Under identical conditions, icSARS-CoV Luc1 and icSARS-
CoV Luc2 displayed 1.5- to 2.0-log reductions in luciferase
expression. Western blot confirmed the reduction in Renilla
luciferase, but not N protein expression, after infection (Fig. 2 B
and C). Northern blot analyses clearly demonstrated the ex-
pected size increases in mRNAs 3–7, but not mRNAs 8–9,
associated with the replacement of ORF7 with the larger Renilla
luciferase gene. Concordant with reduced luciferase protein
expression, TRS-2 clearly reduced expression of subgenomic
mRNA 7 (Fig. 2D).
Rewiring the TRS Transcription Circuit. The entire WT TRS circuit
was replaced with the TRS-2 sequence that differed from the
WT TRS sequence at three nucleotide positions to yield the
icSARS CRG genome. In addition, a second genome was
designed with a scrambled TRS network. The icSARS PRG
genome contained an intact TRS-2 regulatory circuit that was
designed to specifically promote efficient expression of sub-
genomic transcripts (mRNAs 2, 4, 5, and 9) encoding the four
essential structural proteins, S, E, M, and N, respectively.
However,WTTRS-B sites were retained upstream of each of the
group-specific genes ORF3ab, ORF6, ORF7ab, and
ORF8ab. We hypothesized that inefficient leader–body TRS
base pairing should attenuate expression of transcripts encoding
the group-specific genes in the icSARS PRG genome (Fig. 1C).
Recombinant virus icSARS CRG and icSARS PRG both
replicated efficiently in Vero cells, approaching titers of 5.0 
107 pfuml within 20 h after infection, equivalent to WT (Fig.
3A). Growth was slightly delayed after icSARS CRG infection.
Northern blot analyses revealed appropriately sized subgenomic
mRNA species in icSARS CRG-infected cells, typical of WT
SARS-CoV infection (Fig. 3B). Importantly, icSARS PRG
infection was characterized by robust mRNA 1, 2, 4, 5, and 9
synthesis but reduced andor aberrant subgenomic mRNA syn-
thesis driven from theWT TRS-B sites that regulated expression
of the group-specific ORFs. For example, expression of mRNAs
3 and 7 was reduced by 50%, mRNA 6 was of incorrect size,
and mRNA 8 was not detected. Western blot analyses confirmed
abundant levels of the structural proteins S and N in all
recombinant and WT viruses, abundant ORF3a in WT and
icSARS CRG, but little if any ORF3a in icSARS PRG-infected
cultures (Fig. 3C).
Analysis of leader–body TRS junctions in WT icSARS-CoV
and icSARS CRG revealed the expected usage of the appropri-
ate WT or mutant TRS site (data not shown). In icSARS PRG,
Fig. 1. Genome organization of SARS-CoV recombinant viruses. ORF7ab of
SARS-CoV was replaced with the Renilla luciferase gene, resulting in icSARS-CoV
Luc. Second- and third-generation constructs were engineered, which contained
two or three mutations in the ORF7ab TRS, altering the ACGAAC to the double
(TRS-1, ACGGAT) or triple (TRS-2, CCGGAT) mutant in icSARS-CoV Luc1 and
icSARS-CoV Luc2, respectively. The TRS-2 circuit was placed throughout the
icSARS-CoV CRG genome or at select sites within the icSARS-CoV PRG genome to
allowfor structuralgeneexpression.Aseriesofchimericviruseswasassembledby
using the icSARS-CoV and icSARS-CoV CRG molecular clones. (A) Genetic organi-
zation of the icSARS-CoV luciferase replacement viruses. Red boxes represent WT
virus TRS sites. The TRS-B sites are marked by arrows. (B) Organization of the
icSARS-CoV CRG and icSARS-CoV PRG recombinant viruses. TRS sites are indicated
by small red (icSARS-CoV) or blue (icSARS-CoV CRG) squares, respectively. (C)
Genetic organization of chimeric viruses.
Fig. 2. Phenotype of icSARS-CoV Luc recombinant viruses. Infected cells were
lysed at various times after infection. (A) Renilla luciferase light units were
quantified in triplicate.■, icSARS-CoV Luc;, icSARS-CoV Luc1; ‚, icSARS-CoV
Luc2. (B and C) At 12 h after infection, cell lysates were separated on poly-
acrylamide gels and probed with antisera directed against the Renilla lucif-
erase protein (B) or the SARS N protein (C). Lane 1, icSARS-CoV; lane 2,
icSARS-CoV Luc; lane 3, icSARS-CoV Luc1; lane 4, icSARS-CoV Luc2. (D) Overall
mRNA 7 levels were reduced in icSARS-CoV Luc2-infected cultures. Lane 1,
icSARS-CoV; lane 2, icSARS-CoV Luc; lane 3, icSARS-CoV Luc2.









leader–body TRS-2 sites drove expression of subgenomic mR-
NAs encoding the structural proteins, demonstrating efficient
communication between networked leader–body TRS sites. In
contrast, the WT TRS site, ACGAAC, was rarely used for
initiating expression of the group-specific ORF encoding sub-
genomic RNAs (data not shown). Most often, downstream
noncanonical TRS sites were activated, most likely because they
displayed high homology with the leader TRS-2 junction. Ab-
errant leader–body junction sites in mRNA 3 often encoded
N-terminal deletions in the ORF 3a protein (Fig. 4A). The
group-specific ORFs were not essential for SARS-CoV growth
in culture (8).
Remodeled TRS Circuits Are Lethal in RNA Recombinant Genomes.
RNA recombination between WT and icSARS CRG genomes
may generate incompatible TRS regulatory circuits (Fig. 1B). To
test this hypothesis, a series of WT and chimeric recombinant
viruses was engineered (Fig. 1C). Reflecting a double recombi-
nant containing cross-over sites in ORF8 and the replicase ORF,
the icSARS Rec1 genome preserves only the WT TRS-L and N
gene TRS-B circuit. Reciprocal chimeric genomes were also
designed to mimic natural recombinants that would have orig-
inated from a single cross-over event within the S gene. Such
recombinants would have efficient communication between the
WT (icSARS-Rec2) or rewired (icSARS-Rec3) TRS-L and a
TRS-B site regulating mRNA 2 expression but not the remaining
subgenomic mRNAs. Similar recombinants have been noted in
mouse hepatitis virus (15).
Full-length icSARS-CoV, icSARS CRG, and the chimeric
genomes were electroporated into Vero cells. One-fifth of the
cells were used to determine the number of infectious centers
(Fig. 5A). The remaining cells were maintained in complete
medium. In three separate transfection experiments, 103 in-
fectious centers were detected for icSARS CRG and icSARS-
CoV. Under identical conditions, no infectious centers were
detected in icSARS Rec no.1–3 transfected cultures. Moreover,
icSARS-CoV and icSARS CRG virus titers increased from 10
(assay sensitivity) to 107 pfuml by 72 h after electroporation.
No virus was detected in icSARS-Rec no. 1–3 transfected
cultures through 72 h or after three additional serial passages at
48-h intervals (Fig. 5B).
Using RT-PCR, we readily detected leader-containing tran-
scripts in WT and icSARS CRG transfected cultures at 24 h and
increasing abundance by 48 h. These leader-containing tran-
scripts originated at the appropriate network of leader–body
TRS circuits (not shown). In contrast, only low levels of sub-
genomic mRNA transcripts were detected in icSARS Rec no.
1–3 transfected cultures at 24 h, most notably in icSARS Rec no.
2. Leader-containing transcripts had almost disappeared by 48 h
(Fig. 6A). In chimeric viruses, leader-containing RNAs mostly
originated from noncanonical TRS sites located downstream of
the appropriate start location (Fig. 4B). In many cases, nonca-
nonical site usage resulted in large N-terminal deletions in
critical structural genes such as M, which is essential for the
production of infectious progeny virions (Fig. 6B).
Discussion
Genetic recombination is a fundamental evolutionary process,
and recombination repair of attenuated vaccines is not uncom-
Fig. 3. Phenotypic characterization of SARS-CoV recombinants encoding
redesigned TRS networks. The icSARS-CoV CRG and icSARS-CoV PRG were
inoculated onto Vero cells at a multiplicity of infection of 0.1. In addition, RNA
and protein were harvested at 12 h after infection. (A) Recombinant virus
growth in Vero E6 cells. ■, WT Urbani; , icSARS-CoV; Œ, icSARS-CoV PRG; ‚,
icSARS-CoV CRG no. 2. (B) Northern blot analysis of Urbani. Lane 1, icSARS-
CoV; lane 2, icSARS-CoV PRG; lane 3, two different plaque-purified icSARS-CoV
CRG virus-infected cells; lane 4, CRG no. 2; lane 5, CRG no. 3. Asterisks mark
some transcripts noted in icSARS-CoV PRG- and CRG-infected cells. (C) Western
blot analysis evaluating S (Top), N (Middle), or ORF3a (Bottom) expression.
Fig. 4. Structure of icSARS-CoV recombinant virus ORF3a transcripts. Cul-
tures of cells were infected with recombinant viruses. The leader-containing
amplicons were purified by gel electrophoresis, subcloned, and then se-
quenced. (A) Organization of icSARS-CoV PRG ORF3a leader-containing tran-
scripts. (B) ORF3a transcripts expressed in cultures transfected with chimeric
recombinant genome no. 2. Cross-over sites are shown in gray boxes, and
arrows represent the direction of template switching based on the transcrip-
tion attenuation model for CoV RNA synthesis. Underlined ATG represents the
start codon.
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mon (1, 2, 6, 16, 17). RNA recombination occurs when the viral
replicase switches from donor to acceptor templates during
RNA synthesis, followed by the use of the nascent RNA as a
primer for continued RNA synthesis. Replication rates, RNA
secondary structure, genome size, the RNA replicase protein
complex, and host factors regulate the frequency of RNA
recombination events; however, successful inheritance is gov-
erned by the relative fitness of the recombinant progeny (18–21).
Viable recombinants have been described between different
CoV strains and serogroups, including mouse hepatitis virus and
SARS-CoV (22). By rewiring the SARS-CoV transcription
circuit, we identified a method that specifically reduced the
fitness of progeny RNA recombinant viruses.
Empirical studies with a small plant virus suggest that the
successful inheritance of a particular genetic fragment is in-
versely proportional to and constrained by its number of in-
tragenome interactions (23). CoV transcription networks involve
complex interactions among the viral replicase complex, cis and
transacting sequence motifs, and perhaps host factors. This
network probably imparts discrete constraints on the ability of a
genome to evolve by recombination. In the 3 end of the mouse
hepatitis virus genome, gene order rearrangements reduce the
number of recombinant viruses recovered (24). New regulatory
circuits have been designed to control the lysogenic and lytic
phases of infection in phage (25, 26), and genome order has been
remodeled in some phage and mammalian viruses (27, 28).
However, complete redesign of a virus transcription circuit has
not been reported. We engineered a regulatory circuit into the
backbone of a recombinant SARS-CoV that limits the viability
of recombinant progeny. These studies not only describe a
unique paradigm for studying CoV transcription circuit design,
evolution, and function but also allow the engineering of safer
nidovirus live virus vaccine chassis.
Among the Coronaviridae, different TRS motifs have been
described that function in the regulation of transcription. The
engineered TRS CCGGAT circuit is unique and should function
poorly after insertion into any other CoV genome. Our data also
demonstrate that disruption of a TRS-B site specifically debil-
itates expression of its specific subgenomic mRNA and that
mutations in the TRS-L suppress expression of all subgenomic
mRNAs. As with other CoVs, mutations inserted within a
SARS-CoV TRS-B site persisted in subgenomic mRNAs, pro-
viding further support for the transcription attenuation model
(10–12). In chimeric genomes, transcription attenuation was also
guided by downstream sequence motifs that could form base pair
duplexes with the TRS-L; however, these sites were inefficient
and usually mapped within 170 nt. Occasionally, leader-
containing transcripts originated within flanking sequences ad-
jacent to the core TRS sequence. These data suggest that a 9–12
nt TRS circuit that included some upstreamdownstream flank-
ing nucleotides might result in more stable artificial circuits.
Interestingly, noncanonical TRS sites that were transcriptionally
active in the icSARS PRG genome were silent in the icSARS
CRG genome (Fig. 3B). We believe that TRS recognition is
hierarchical and based on higher order RNA structure, local
RNA structure, replicase function, and TRS-LTRS-B sequence
homology. In the absence of a perfect TRS match, the tran-
scription network selects the next best sequence match in the
Fig. 5. Infectivity of WT and chimeric recombinant RNAs. Cultures were
transfected with RNA transcripts encoding the icSARS-CoV, icSARS-CoV CRG,
icSARS-CoV Rec1, icSARS-CoV Rec2, and icSARS-CoV Rec3 genomes. Cells were
plated onto monolayers and overlaid with medium containing agarose for
determination of infectious centers or placed into 25-cm2 flasks. (A) Infectious
center assay of recombinant transcripts. (B) Virus titers at different times after
transfection. ■, icSARS-CoV; , icSARS-CoV CRG.
Fig. 6. Leader–body TRS junctions in WT and chimeric recombinant viruses.
Intracellular RNA was isolated at 24 and 51 h after transfection. Using leader-
and ORF7-specific primer pairs, leader-containing amplicons were separated
on agarose gels, excised, subcloned, and sequenced. (A) Leader-containing
amplicons in transfected cultures. (B) Leader–body junctions in mRNA 5
transcripts encoding the SARS M glycoprotein. Although the expected leader–
body junctions were noted for icSARS-CoV and icSARS-CoV CRG, noncanonical
mRNA 5 TRS sites were identified in chimeric viruses. Cross-over site locations
are shown by gray boxes, and arrows represent the direction of template
switching. Underlining marks the ATG start codon.









proximal locale, but at reduced rates. The exact nature of this
transcription network remains largely unexplored.
Chimeric genomes were crippled because incompatible TRS
circuitry was less efficient, reducing mRNA synthesis. In the
icSARS-CoV Rec no. 2 chimera, nearby noncanonical sites were
preferentially engaged in subgenomic transcription. These non-
canonical sites were defined by sequences that provided limited
base pair duplex formation between negative strands and TRS-L.
Among mRNA 5 transcripts, 75% encoded for M glycoproteins
with N-terminal 32 or 83 amino acid deletions. No E tran-
scripts were noted. Both M glycoprotein and E protein are
essential for efficient maturation and release (29, 30). Inevitably,
the fatal phenotype likely resulted from both inefficient pro-
duction and mutation of essential structural proteins such as E
and M (31, 32). Excess truncated M glycoprotein may also
establish a dominant-negative phenotype that further impedes
assembly and release. Because the N protein functions as an
enhancer of subgenomic transcription and genome replication
and infectivity, limited N protein production would also function
to suppress expression of subgenomic ORFs (33, 34). It is
intriguing that noncanonical sites were most readily detected in
chimeras containing the renetworked TRS-2-L site (CCGGAT)
linked with WT TRS-B sites, because many fewer leader-
containing transcripts were detected in chimeras with WT
TRS-L (icSARS-CoV Rec1,3). Evolutionary pressure may have
minimized the number of cryptic noncanonical TRS interactions
located within the WT genome, pressures that were never
applied to the icSARS-CoV CRG genome. Mapping noncanoni-
cal starts may allow for the efficient design of quiescent TRS sites
in the icSARS CRG backbone that are calculated to express
subgenomic mRNAs encoding N-terminal deletions in critical
structural proteins, but only after recombination events
with WT.
The strategy described herein provides a rational approach for
minimizing viability of progeny RNA recombinant CoVs; how-
ever, double intragenic recombinants, especially within the
20-kb SARS replicase ORF, would not be affected by the
redesigned TRS circuitry. A fundamental theme in postgenomic
research and systems biology will be to elucidate the complex
interactions that regulate virus gene expression, polyprotein
processing, transcription and replication, genome packaging,
and assembly and release. In addition to the nidovirus TRS
circuit paradigm, many positive-strand RNA viruses encode
proteases that cleave large polyproteins at select sites. Remod-
eling protease cleavage site specificity might establish a genetic
trap that is triggered by recombination events that scrambled
different polyprotein processing networks (35, 36). Experimen-
tal phage evolution suggests an alternative approach (37, 38).
Compensatory mutations occur when fitness loss caused by one
mutation is remedied by its epistatic interactions with a se-
cond mutation in a different genome location. Often, comp-
ensatory mutations are extragenic and independently deleteri-
ous in the parent genome (38). Vaccine chassis that contain one
or more sets of compensatory mutations will encode genetic
traps that are triggered by recombination events that disrupt
epistatic interactions. Complex interaction networks in genome
encapsidation and virion formation might also be exploited in
the design of recombination-resistant viruses as well (32, 39).
Live virus vaccine platforms that encode new regulatory circuits
provide a means toward enhancing safety and stabilizing atten-
uating mutations, especially against recombination repair.
Methods
Viruses and Cells. The Urbani and icSARS strains of SARS-CoV
(AY278741), icSARS-CoV Luc, icSARS-CoV Luc1, icSARS-
CoV Luc2, and the icSARS CRG and PRG recombinant viruses
were propagated on Vero E6 cells as described in ref. 8. Cultures
of Vero E6 cells were infected at a multiplicity of infection of 0.1
pfu for 1 h, and the samples were titered by plaque assay. All
virus work was performed in a biological safety cabinet in a
biosafety level 3 laboratory containing redundant exhaust fans as
described in ref. 8.
Construction of Renilla Luciferase Encoding SARS-CoV Recombinant
Clones. Plasmid DNA was amplified in One Shot Top 10 chem-
ically competent cells (Invitrogen, Carlsbad, CA) and purified
with the Qiaprep miniprep kit (Qiagen, Valencia, CA). DNA
fragments were isolated from 1.0% agarose gels with the Qia-
quick gel extraction kit (Qiagen) and visualized by using Dark
Reader technology (Clare Chemical Research, Denver, CO).
The six subgenomic cDNA clones (A–F) span the SARS-CoV
genome (9). ORF 7ab, located within SARS F (nt 27273–
27772), was replaced with the Renilla luciferase gene as de-
scribed with GFP in ref. 14.
To introduce mutations into the ORF7 TRS site, a forward
primer (Ppum3: 5-GCTGTGACATTAAGGACCTGC-
CAAAAG-3) was used concurrently with reverse primers
(3MUT3: 5-AGGTGCACCTGCAGCCATTTTAATT-
TATCCGGTTTATGGATA-3 or 2MUT3: 5-AGGTGCAC-
CTGCAGCCATTTTAATTTATCCGTTTTATGGATA-3).
Amplicon 1 (TRS-2) contained three mutations (CCGGAT),
whereas amplicon 2 (TRS-1) had two mutations (ACGGAT) in
the TRS site flanked by AarI and PpumI sites. A third amplicon
(AMP3), f lanked by AarI and PacI sites, was amplified with
forward primer (3MUT5: 5-GGTGCACCTGCAAATAAAT-
GGCTTCCA-3) and reverse primer (PacI3: 5-TAAAGT-
GAGCTCTTAATTAATTACTGCTCG-3). After digestion,
AMP1 and AMP2 were ligated separately to AMP3, and the
1.34-kb cDNA was cloned into pTOPO PCR-XL (Invitrogen).
The mutated TRS sites were inserted into the icSARS WT
luciferase (icSARS-CoV Luc) cDNA F construct and verified by
sequence.
Construction of SARS Plasmids Containing Redesigned TRS Circuits.To
create the TRS-L CCGGAT sequence, the SARS A plasmid was
amplified with primer set M13R3 (5-CAGGAAACAGCTAT-
GAC-3) and MuL1 (5-AAAATCCGGTTAGAGAACA-
GATCTACAAGAG-3) or MuL1 (5-CTAACCGGATTTTA-
AAATCTGTGTAGCTGTC-3) and SARS 453 (5-ATA-
GGGCTGTTCAAGCTGGGG-3). After overlapping PCR, the
resulting 620-bp product was cloned and sequenced. The insert
was digested with MluI and AvrII and inserted into the SARS A
plasmid. To mutate the spike (S) gene TRS, the SARS E fragment
was PCR-amplified with primer sets SARS no. 37 (5-TGCTG-
GCTCTGATAAAGGAG-3) and MuSgene (5-NNNCACCT-
GCACATATCCGGTTAGTTGTTAACAAGAATATCAC-3)
or MuSgene (5-NNNCACCTGCAACCGGATATGTT-
TATTTTCTTATTATTTCTTACTCTC-3) and no. 10 AgeI
(5-CATCAAGCGAAAAGGCATCAG-3). These fragments
were digested with restriction enzymeAarI, ligated, and subcloned.
The mutated amplicon was digested with BsmBI and AgeI and
inserted into the SARS E plasmid.
The SARS F plasmid containing the remaining TRS sites




GTACTCATTCGTTTCGG-3) and MuMgene (5-NNNCA-
CCTGCAATAGTTAATCCGGTTAGACCAGAAGAT-CAG-
GAAC-3); and MuMgene (5-NNNCACCTGCGGATTAAC-
TATTATT-ATTATTCTGTTTGG-3) and 28033 (5-TAC-
CAACACCTAGCTATAAGC-3). The three amplicons were di-
gested with AarI, directionally ligated, and subcloned. A clone
containing the new consensus sequence CCGGAT for the E andM
genes was digested with SwaI and NdeI and inserted into the SARS
F plasmid (SARS F muEM). The SARS N gene TRS was
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constructed with MuNgene1 (5-GCTGCATTTAGAGACG-
TACTTGTTGTTTTAAATAACCGGATAAAT-TAAAAT-
GTCTGATAATGG-3) and SARS 3 Ng (5-TTAATTAAT-
TATGCCTGAGTTGAATCAGCAG-3). The product was
digested with BsmBI and inserted into plasmid SARS F muEM
(SARS F muEMN). To alter the ORF 3a TRS, amplicons were
isolated with primer sets [SARS no. 44 and SARSX1 (5-CGT-
CTCATGTGTAATGTAATTTGACACCC-3) or SARSX1
(5-CGTCTCACA-CATAACCGGATTTATGGATTTGTT-
TATGAGATTTTTTAC-3) and 28033] and joined by ligation
at the flanking BsmBI sites. This product was inserted into SARS
F muEMN by using SwaI-NdeI sites (SARS F mu3aEMN).
Primer sets [SARS no. 47 (5-GTGCTTGCTGTTGTCTACAG-
3) and SARSX3 (5-CGTCTCCGTCCG-GGATGTAGCCA-
CAGTGATCTC-3), SARSX3 (5-CGTCTCCGGACGCTT-
TCTT-ATTACAAATTAGGAG-3) and SARSX4 (5-CGT-
CTCTCATATCCGGTTTATGGATAA-TCTAACTCCATAG-
3), and SARSX4 (5-CGTCTCATATGAAAATTATTCTCT-
TCCTG-AC-3) and 28033] were used to generate three PCR
fragments that were digested with BsmBI, ligated with T4 DNA
ligase, and subcloned. A clone containing only the required changes
in TRS sites regulating subgenomic transcription of ORF6 and 7
was digested with AvrII and inserted into plasmid SARS Fmu
3aEMN (SARS Fmu 3aEM67N). Finally, primer set
SARS no. 48 (GGACTTTCAGGATTGCTATTTG) and
SARSX5 (CGTCTCATCCGGT-TAGACTTTGGTACAAG-
GTTC) and set SARSX5 (CGTCTCCCGGATATGAAACT-
TCTCATTGTTTTGAC) and SARS3X5 (NNNTTAATTAAT-
TAATTT-GTTCGTTTATTTAAAACAACA) created PCR
products that were similarly joined by using BsmBI and T4 DNA
ligase. This product was introduced into plasmid SARS Fmu
3aEM67N by using the NdeI-BstEII restriction sites. This
final construct (SARS F CRG) was verified by sequence.
Isolation of Recombinant Viruses. The SARS full-length cDNAwas
assembled, and full-length transcripts were synthesized and
mixed with polyadenylated N gene transcripts and then electro-
porated into cells (9, 40). Viruses were plaque-purified in Vero
E6 cells, and stock was grown in 75-cm2 flasks.
Northern Blot Analysis. Intracellular RNA was isolated by using
RiboPure reagents (Ambion, Austin, TX) at 12 h after infection.
The mRNA was isolated by using Qiagen’s Oliogtex mRNA
spin-column reagents, treated with glyoxal, and separated on
agarose gels by using NorthernMax-Gly (Ambion). The RNA
was transferred to BrightStar-Plus membrane (Ambion) for 4–5
h, cross-linked by UV light, prehybridized, and probed with an
N gene-specific oligodeoxynucleotide probe (5-cttgactgccgc-
ctctgctbtbccctbctbgcb-3; biotinylated nucleotides are designated
with a superscript ‘‘b’’). Blots were hybridized overnight and
washed with low- and high-stringency buffers, and the filters
were incubated with alkaline phosphatase-conjugated strepta-
vidin. The filters were incubated with the chemiluminescent
substrate CDP-STAR, overlaid with film, and developed.
Western Blot Analysis. Twelve hours after infection, cells were
washed in 1 PBS, lysed in buffer containing 20 mM TrisHCL
(pH 7.6), 150 mM NaCl, 0.5% deoxycholine, 1% Nonidet P-40,
and 0.1% SDS, and postnuclear supernatants were added to an
equal volume of 5 mM EDTA0.9% SDS. Samples were then
heat-inactivated for 30 min at 90°C, loaded onto 4–20% Crite-
rion gradient gels (Bio-Rad, Hercules, CA), and transferred to
PVDF membrane (Bio-Rad). Blots were probed with polyclonal
mouse sera against the SARS-CoV ORF3a, S, or N proteins
diluted 1:200 and developed by using ECL chemiluminescence
reagents (GE Healthcare, Piscataway, NJ). Renilla luciferase
expression was verified by using commercial antibodies (Chemi-
con International, Temecula, CA).
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